Juno study shows 60 percent of lymphoma patients in remission after immunotherapy treatment by Clare McGrane on December 6, 2016December 6, 2016 at 9:57 am New data from Seattle’s Juno Therapeutics shows promising results for one of its immunotherapy treatments, JCAR017. The drug was studied as a treatment for severely sick patients with non-Hodgkin lymphoma, and the most… Read More